VERNALIZATION1 (VRN1) is required in the model plant Arabidopsis thaliana for the epigenetic suppression of the floral repressor FLC by prolonged cold treatment. Stable suppression of FLC accelerates flowering, a physiological process known as vernalization. VRN1 is a 341-residue DNA-binding protein that contains two plant-specific B3 domains (B3a and B3b), a putative nuclear localization sequence (NLS) and two putative PEST domains. VRN1 208-341 includes the second B3 domain and a region upstream that is highly conserved in the VRN1 orthologues of other dicotyledonous plants. VRN1 208-341 was crystallized by the hanging-drop method in 0.05 M sodium acetate pH 6.0 containing 1.0 M NaCl and 18%(w/v) PEG 3350. Preliminary X-ray diffraction data analysis revealed that the VRN1 208-341 crystal diffracted to 2.1 Å and belonged to space group C2, with unit-cell parameters a = 105.2, b = 47.9, c = 61.2 Å , = 90.0, = 115.4, = 90.0 . Assuming that two molecules occupy the asymmetric unit, a Matthews coefficient of 2.05 Å 3 Da À1 and a solvent content of 40.1% were calculated.
Introduction
Vernalization is a physiological process in which prolonged cold (namely winter) accelerates flowering. In Arabidopsis, vernalization is predominantly achieved by repressing the MADS-box floral repressor FLOWERING LOCUS C (FLC; Michaels & Amasino, 1999; Sheldon et al., 1999) . Using molecular-genetic approaches, Arabidopsis vernalization has been shown to require a number of proteins including VIN3, a plant homeodomain (PHD) finger protein whose expression is induced by prolonged cold (Sung & Amasino, 2004) , VRN5, a VIN3-related protein that is constitutively expressed (Greb et al., 2007; Sung, Schmitz et al., 2006) , VRN2, a homologue of the Polycomb protein Su(z)12, a well characterized chromatin regulator in Drosophila and humans (Gendall et al., 2001) , and VERNALIZATION1 (VRN1), a DNA-binding protein (Levy et al., 2002) . Maintenance of FLC silencing also requires the Arabidopsis homologue of HETEROCHROMATIN PROTEIN1 (Mylne et al., 2006; Sung, He et al., 2006) . Recently, TAP-tagged VRN5 was found to be able to pull down a complex of proteins including the aforementioned VRN2 and VIN3 with Polycomb core proteins FIE (an ESC homologue), MSI1 (a p55 homologue) and a PHD-finger protein VEL1 (De Lucia et al., 2008) . Vernalization stably suppresses FLC via changes to the histones associated with the FLC locus, which result in the mitotic stability of vernalization (Bastow et al., 2004; Sung & Amasino, 2004) .
VRN1 is a plant-specific protein and so far appears to only have dicotyledonous homologues. VRN1 possesses two B3 DNA-binding domains, putative PEST protein-turnover domains and nuclear localization sequences (Levy et al., 2002) . Overexpression of VRN1 protein does not affect the requirements for vernalization but caused very deformed and early flowering plants, revealing that VRN1 needs other factors to suppress FLC and that VRN1 has additional roles in plant development (Levy et al., 2002) . In vitro, recombinant fulllength VRN1 protein was shown to bind naked dsDNA in a nonsequence-specific manner (Levy et al., 2002) . A fully functional genomic VRN1-GFP fusion associated throughout the nucleus in vivo and remained associated with mitotic chromosomes (Mylne et al., 2006) . Immunolocalization showed VRN1 to be excluded from heterochromatic chromocentres. VRN1 protein dissociated from nuclei undergoing meiosis and this was supported by a dramatic drop in mRNA expression in pollen (Mylne et al., 2006) .
Although full-length VRN1 protein may be produced in Escherichia coli, it is unstable and even rapidly prepared protein extracts exhibit degradation. Following purification from the degraded forms, full-length VRN1 continues to degrade in vitro. We produced a stable 134-residue fragment VRN1 208-341 which includes the second B3 domain (B3b) and a region upstream that is both highly conserved in the VRN1 orthologues of other dicotyledonous plants and predicted to possess helical secondary structure. Here, we report the crystallization and preliminary X-ray analysis of A. thaliana VRN1 208-341 .
Materials and methods

Expression and purification
A plasmid pET19b-V1 (Levy et al., 2002) containing a full-length A. thaliana VRN1 (At3g18990) open reading frame was PCR amplified using primers JM91 (5 0 -GAA TTC GGT ACC GGA TCC CGT TCA AAG TTC TAC GAG AGT GCT-3 0 ) and JM93 (5 0 -ACG CAC GCA CGC GTC GAC TCA GAC GTA CTC GTT GAC TCG AAA-3 0 ). The product was digested with BamHI and SalI (sites shown in bold in the primer sequences above) and ligated into the BamHI/SalI sites of pQE30 (Qiagen). This construct introduces an N-terminal sequence MRGSHHHHHHGS to the 134 residues of VRN1 from Arg208 to Val341 (total deduced molecular weight of 16 988 Da).
The pQE30-VRN1 208-341 plasmid (JMDNA27) and pREP4 (Qiagen) were co-transformed into E. coli strain BL21 (Novagen) and selected on 100 mg ml À1 ampicillin and 35 mg ml À1 kanamycin Luria-Bertani (LB) agar plates. A single colony was picked and grown overnight at 310 K in 40 ml LB broth containing 100 mg ml À1 ampicillin and 35 mg ml À1 kanamycin. This culture was split to start two separate 500 ml LB cultures containing 100 mg ml À1 ampicillin and 35 mg ml À1 kanamycin. When the cultures had reached log-phase growth (OD 600 nm = 0.8), they were moved to 289 K and VRN1 208-341 protein expression was induced by addition of isopropyl -d-1-thiogalactopyranoside to 1 mM and growth overnight.
Cells were pelleted and resuspended in 50 mM Tris-HCl pH 8.0, 1 M sodium chloride, 30 mM imidazole, 10 mM benzamidine hydrochloride and lysed by five passes through a French press at 6.9 MPa. The lysate was cleared by centrifugation and loaded onto a PolyPrep column (BioRad) containing 3 ml chelating (Ni-NTA) Sepharose (GE Heathcare) pre-loaded with 10 ml 100 mM nickel sulfate. The column was washed with 50 ml 50 mM Tris-HCl pH 8.0, 1 M sodium chloride, 30 mM imidazole and the VRN1 208-341 protein was eluted from the column with 11 ml 50 mM Tris-HCl pH 8.0, 1 M sodium chloride, 250 mM imidazole. The protein was further purified by sizeexclusion chromatography using a Sephacryl S100 column (GE Healthcare) in buffer containing 50 mM sodium phosphate pH 7.0, 150 mM NaCl and 1 mM DTT. Pure VRN1 208-341 was dialysed into 10 mM HEPES pH 7.0, 50 mM sodium chloride, 5 mM DTT and concentrated for crystallization by centrifugation in an Amicon Ultra-4 concentrator with a 5 kDa cutoff (Millipore). A Coomassiestained gel of the purified VRN1 208-341 protein is shown in Fig. 1(a) .
Crystallization
Crystallization-condition screening was performed at 293 and 277 K using the following eight commercial screening kits: lization experiments were stored and imaged using two RockImagers (Formulatrix), with one set at 277 K and the other at 293 K.
Optimization experiments were set up in 24-well VDXm plates (Hampton Research) that contained 400 ml well solution; the drop was comprised of 1 ml protein solution and 1 ml well solution on siliconized glass cover slides (Hampton Research).
Crystals were placed in cryo-solution [sodium acetate pH 4.5 containing 1.0 M NaCl, 20%(w/v) PEG 3350 and 20%(v/v) ethylene glycol] for less than a minute before being placed directly in the cryostream.
Data collection and refinement
Diffraction data were collected on a Rigaku FR-E copper rotatinganode generator operated at 45 kV and 45 mA with Osmic Confocal Vari-Max HF optics at a wavelength of 1.5418 Å . The crystal was kept at 100 K during data collection using a CRYO Industries of America CRYOCOOL-LN2 gas-stream cooler. 360 images were collected with Á' = 0.5 and a crystal-to-detector distance of 60 mm. The detector was a Rigaku Saturn 944 CCD.
Data were processed using CrystalClear 1.4 (Rigaku Corporation).
Results and discussion
In the initial screening trials, six conditions were found to produce crystalline precipitate at the two temperatures (277 and 293 K): Systematically Controlled Crystallization Screen Set 101 conditions 79 and 88 at 277 K, Index Screen conditions 9 and 10 at 277 K and Pact Premier conditions 35 and 61 at 277 and 293 K, respectively. Five of these conditions were reproduced in an optimization round that again used the hanging-drop format. Optimization experiments for Systematically Controlled Crystallization Screen Set 101 conditions 79 and 88 were designed in a shallow-gradient format and used to generate crystals for diffraction studies.
VRN1 208-341 crystals grown using conditions based on the commercial condition Systematically Controlled Crystallization Screen Set 101 condition 79 [0.05 M sodium acetate pH 5.0 containing 15%(v/v) PEG 3350 and 1.0 M NaCl] appeared as clusters ( Fig. 1b ) from which single crystals could be separated for X-ray diffraction studies. A crystal (0.2 Â 0.05 Â 0.05 mm) separated from a cluster grown at 277 K in 0.05 M sodium acetate pH 6.0 containing 1.0 M NaCl and 18%(w/v) PEG 3350 (based on condition 79) diffracted to 2.1 Å resolution (Table 1, Fig. 2 ). The crystal belonged to space group C2 with unit-cell parameters a = 105.2, b = 47.9, c = 61.2 Å , = 90.0, = 115.4, = 90.0 . Assuming the presence of two protein molecules per asymmetric unit, acceptable values were obtained for the Matthews coefficient (2.05 Å 3 Da À1 ) and solvent content (40.1%; calculated using http://www.scripps.edu/cgi-bin/cdputnam/protcalc3; Matthews, 1968 
Figure 2
Diffraction image from native VRN1 208-341 (Cu K, wavelength = 1.5418 Å ). An enlargement of the boxed region is shown on the right. The crystal diffracted to 2.1 Å resolution.
2004) and At1g16640 (Waltner et al., 2005) . Despite only sharing 26% sequence identity, the tertiary structures of these two B3 domains are similar (backbone r.m.s.d. ' 2 Å ; Waltner et al., 2005) . Both structures were determined using NMR spectroscopy; this report therefore describes the first crystallization of a B3-domain protein.
The 99-amino-acid B3-domain region of VRN1 208-341 (i.e. VRN1 Phe243-Val341) has 25% identity to the B3 domain of RAV1 and 18% identity to At1g16640. Attempts to use these two NMR structures (RAV1, PDB code 1wid; At1g16640, PDB code 1yel) as models for a molecular-replacement solution of these VRN1 208-341 data using Phaser (McCoy, 2007) have so far failed. We are therefore planning to produce an SeMet derivative of this protein for structure determination by SAD or MAD phasing.
